The revolutionary BiVACOR heart device was moved to Phase 2 of FDA trials after success in five human patients.
Adding engineered human blood vessel-forming cells to islet transplants boosted the survival of the insulin-producing cells ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback